Table 2.

In vitro susceptibilities to fluconazole and itraconazole of BSI isolates of various species of Candida from 1997 and 1998

SpeciesYrNo. of isolatesAntifungal agentMIC (μg/ml)a% Rb
Range50%90%
C. albicans1997c163Fluconazole0.12–>1280.251.00.6
Itraconazole0.015–>8.00.060.120.6
1998181Fluconazole0.12–>1280.250.51.1
Itraconazole0.008–>8.00.030.122.2
C. glabrata1997c46Fluconazole1.0–>1288.0328.7
Itraconazole0.12–>8.00.52.036.9
199858Fluconazole0.25–1288.0165.2
Itraconazole0.06–>8.00.52.032.8
C. parapsilosis1997c48Fluconazole0.12–4.01.02.00
Itraconazole0.015–0.50.120.250
199847Fluconazole0.25–4.00.51.00
Itraconazole0.015–0.50.060.250
C. tropicalis1997c24Fluconazole0.25–4.00.52.00
Itraconazole0.03–1.00.120.54.2
199828Fluconazole0.25–8.00.51.00
Itraconazole0.015–1.00.060.53.6
C. krusei1997c6Fluconazole32–6432100
Itraconazole0.12–2.01.066.6
19984Fluconazole8.0–3232100d
Itraconazole0.12–0.50.250
  • a 50% and 90%, MICs for 50 and 90% of isolates tested, respectively.

  • b % R, percent resistant as determined by using interpretive breakpoint criteria of the NCCLS (13): fluconazole resistance, ≥64 μg/ml; itraconazole resistance, ≥1.0 μg/ml.

  • c Adapted from the work of Pfaller et al. (20).

  • d Isolates of C. krusei are considered resistant to fluconazole, regardless of the MIC.